This is the authors' abstract. We don't add key points for this paper.
Not all patients refractory to sorafenib were candidates for second-line therapy. A Child-Pugh score of A5 at sorafenib initiation was an important and favorable factor related to eligibility for second-line therapy and good outcomes.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Kuzuya et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: